NTRK3 F617L

CI-VAR-00001129Explore in graph →CIViC 3468

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor1
NTRK3 F617L	Larotrectinib	Predictive	C	Supports Resistance	2	accepted	EID9592 A 58-year-old male with NTRK-fusion positive gastrointestinal stromal tumour (GIST) demonstrated initial response to Larotrectinib but progressed after developing a gatekeeper mutation (TRKC F617L). PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
Solid Neoplasm1
NTRK3 F617L	Larotrectinib	Predictive	A	Supports Resistance	2	submitted	EID11571 In the LOXO-TRK-14001 trial, all eight patients with TRK-fusion positive cancer had objective response to larotrectinib. The FDA approval for this indication excludes patients with known resistance mu… (full text at CIViC) PMID 30624546 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.